Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
We recently published an article titled Why These 10 Dividend Stocks Are Declining? In this article, we are going to take a ...
Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...